Back to top
more

Insys Therapeutics, Inc. (INSY)

(Delayed Data from NSDQ)

$4.19 USD

4.19
303,567

+0.04 (0.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up

IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.

    Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues

    Hill-Rom Holdings (HRC) rides high on international growth and product innovation.

      NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View

      NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.

        Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2

        Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.

          LeMaitre Vascular (LMAT) Worth a Look: Stock Jumps 19.5%

          LeMaitre Vascular, Inc. (LMAT) shares jumped above 19% in the last trading session.

            Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1

            Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.

              GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates

              Sluggish performance by the U.S. & Canada international and manufacturing/wholesale segments marred second-quarter results for GNC Holdings (GNC).

                Align Technology (ALGN) Beats on Q2 Earnings and Revenues

                Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.

                  QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View

                  QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.

                    McKesson (MCK) Misses Earnings Estimates in Q1, Raises View

                    McKesson's (MCK) performance was muted in the first quarter owing to branded to generic conversions and competition in its pharmacy business.

                      Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss

                      Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.

                        CONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2

                        CONMED's (CNMD) strong global performance was a key highlight in the second quarter of 2017.

                          LabCorp (LH) Beats on Q2 Earnings and Sales, Guidance Up

                          LabCorp's (LH) dull Covance Drug Development performance is offset by solid growth in Diagnostics. Increased guidance raises hope.

                            Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised

                            Chemed (CHE) rides high on Roto-Rooter in second-quarter 2017. An encouraging bottom-line projection raises hopes.

                              Express Scripts (ESRX) Earnings Top in Q2, FY17 View Up

                              Express Scripts (ESRX) perform well in the second quarter on the back of operational cost improvement backed by focus on home delivery and specialty services.

                                PetMed Express (PETS) Tops Earnings, Revenue Estimates in Q1

                                PetMed (PETS) initiated fiscal 2018 with better-than-expected results in the first quarter, beating both earnings and revenues.

                                  Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up

                                  Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.

                                    Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas

                                    Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.

                                      Align Technology Hits a 52-Week High on Solid Prospects

                                      Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $157.86 on Jul 17, eventually closing a bit lower at $156.21.

                                        Medtronic InterStim System Shows Five-Year Positive Results

                                        Medtronic plc (MDT) has announced that its InterStim system provides sustained long-term efficacy and improved quality of life for overactive bladder (OAB) patients at the end of five years.

                                          Company News for July 17, 2017

                                          Companies In the News are: CYBR,ARNC,T,INSY,TWX

                                            Hill-Rom (HRC) at 52-Week High: What's Driving the Stock?

                                            Share price of Batesville, IN-based Hill-Rom Holdings, Inc. (HRC) scaled a new 52-week high of $84.17 on Jul 14.

                                              MedTech Industry Outlook - July 2017

                                              The overall expectation is that President Trump's legislative change for MedTech will result in lower taxes and regulation for the industry as a whole.

                                                Arpita Dutt headshot

                                                Play the Marijuana Rush as First Marijuana-Focused ETF Launches

                                                The medical marijuana industry has been gaining a lot of importance and attracting interest from investors over the last few quarters with companies like GW Pharma (GWPH) making headlines.

                                                  Zacks Industry Outlook Highlights: Varian Medical Systems, T2 Biosystems, Edwards Lifesciences, INSYS Therapeutics and Cerner

                                                  Zacks Industry Outlook Highlights: Varian Medical Systems, T2 Biosystems, Edwards Lifesciences, INSYS Therapeutics and Cerner